Dopaminergic and opioidergic mediations of tricyclic antidepressants in the learned helplessness paradigm

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 3, 1999, Pages 541-548

  Besson, A ^a   Privat, A M ^a   Eschalier, A ^a   Fialip, J ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Antidepressants; Dopamine; Haloperidol; Learned helplessness; Opioid; Rat

Indexed keywords

AMINEPTINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; HALOPERIDOL; IMIPRAMINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNED HELPLESSNESS; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DESIPRAMINE; DIBENZOCYCLOHEPTENES; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; ESCAPE REACTION; HALOPERIDOL; HELPLESSNESS, LEARNED; IMIPRAMINE; MALE; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2;

EID: 0032855947     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00102-1     Document Type: Article

References (71)

1. Algeri S., Brunello N., Catto E., Mennini R., Ponzio F. Biochemical effect of some new proposed antidepressant drugs on the monoaminergic systems in the rat brain. Garattini S. Depressive disorders. 1978;155-168 Schattauer Verlag, Stuttgart.
2. Baraldi M., Poggioli R., Santi M., Veroni A.V., Bertolini A. Antidepressants and opiates interactions. Pharmacological and biochemical evidences Pharmacol. Res. Commun. 15:1983;843-857.
3. Besson A., Privat A.M., Eschalier A., Fialip J. Effects of morphine, naloxone and their interaction in the learned helplessness paradigm in rats. Psychopharmacology (Berlin). 123:1996;71-78.
4. Besson A., Privat A.M., Eschalier A., Fialip J. Reversal of learned helplessness by morphine in rats. Involvement of a dopamine mediation Pharmacol. Biochem. Behav. 60:1998;519-525.
5. Biegon A., Samuel D. Interaction of tricyclic antidepressants with opiate receptors. Biochem. Pharmacol. 20:1980;460-464.
6. Blier P., De Montigny C., Chaput Y. Modifications of the serotonergic system by antidepressant treatments. Implication for the therapeutic response in major depression J. Clin. Psychopharmacol. 7:1987;24S-35S.
7. Bonnet J., Chagraoui A., Protais J., Costentin J. Interaction of amineptine with the neuronal dopamine uptake system. Neurochemical in vitro and in vivo studies J. Neural Transm. 69:1987;211-220.
8. Briley M., Prost J.F., Moret C. Preclinical pharmacology of minalcipram. Int. Clin. Psychopharmacol. 4:1996;9-14.
9. Carboni E., Tanda G., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex. Evidence that dopamine is taken up in vivo by noradrenergic terminals J. Neurochem. 55:1990;1067-1070.
10. Ceci A., Garattini S., Gobbi M., Mennini T. Effect of long-term amineptine on pre-and postsynaptic mechanisms in rat brain. Br. J. Pharmacol. 88:1986;269-275.
11. Cervo L., Grignaschi G., Samanin R. The role of the mesolimbic dopaminergic system in the desipramine effect in the forced swimming test. Eur. J. Pharmacol. 178:1990;129-133.
12. Chaput Y., De Montigny C., Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 5:1991;219-229.
13. 2 receptors in chronic fluoxetine-treated rats. Eur. J. Pharmacol. 322:1997;123-127.
14. Cooper S.J. Interactions between endogenous opioids and dopamine. Implications for reward and aversion Willner P., Scheel-Kruger J. The mesolimbic dopamine system. From motivation to action:1991;331-336 Wiley, Chichester.
15. Devoize J.L., Rigal R., Eschalier A., Trolese J.F., Renoux M. Influence of naloxone on antidepressant drug effects in the forced swimming test in mice. Psychopharmacology (Berlin). 84:1984;71-75.
16. Di Chiara G., North R.A. Neurobiology of opiate abuse. Trends Pharmacol Sci. 13:1992;162-185.
17. Di Chiara G., Tenda G. Blunting of reactivity of dopamine transmission to palatable food. A biochemical marker of anhedonia in the CMS model? Psychopharmacology (Berlin). 134:1997;351-353.
18. Dziedzicka-Wasylewska M., Rogoz R. The effect of prolonged treatment with imipramine and electroconvulsive shock on the levels of endogenous enkephalins in the nucleus accumbens and the ventral tegmentum of the rat. J. Neural Transm [Gen Sect]. 102:1995;221-228.
19. Frazer A. Pharmacology of antidepressants. J. Clin. Psychopharmacol. 17(Suppl. 1):1997;2S-18S.
20. Geoffroy M., Christensen A.V. Psychomotor stimulants versus antidepressants in the learned helplessness model of depression. Drug Dev. Res. 29:1993;48-55.
21. Goodwin G.M. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J. Clin. Psychiatry. 57(Suppl. 4):1996;9-13.
22. Gysling K., Wang R.Y. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res. 277:1983;119-127.
23. Hamon M., Gozlan H., Bourgoin S., Beneliel J.J., Mauborgne A. Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology. 26:1987;531-539.
24. Harris J.C. Experimental animal modeling of depression and anxiety. Psychiatr. Clin. N. Am. 12:1989;815-835.
25. 3H]DuP734, a novel sigma ligand. Brain Res. 598:1992;76-86.
26. Hughes Z.A., Stanford S.C. Increased noradrenaline efflux induced by local infusion of fluoxetine in rat frontal cortex. Eur. J. Pharmacol. 317:1996;83-90.
27. Ichikawa J., Meltzer H.Y. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur. J. Pharmacol. 281:1995;255-261.
28. Invernizzi R., Pozzi L., Vallebuona F., Bonini I., Sacchetti G., Samanin R. Effect of amineptine on regional extracellular concentrations of dopamine and noadrenaline in the rat brain. J. Pharmacol. Exp. Ther. 262:1992;769-774.
29. Isenberg E., Cicero T.J. Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. Eur. J. Pharmacol. 103:1984;57-63.
30. Jenner P., Marsden C.D. Substituted benzamide drugs as selective neuroleptic agents. Neuropharmacology. 20:1981;1285-1292.
31. Jimenez-Rivera C.A., Segarra O., Santacana G., Hoffman T., Savage D.D., Weiss G.K. Chronic imipramine treatment induces downregulation of alpha-2 receptors in rat's locus coeruleus and A2 region of the tractus solitarius. Life Sci. 58:1996;287-294.
32. Johnson R.P., Sar M., Stumpf W.E. A topographic localization of enkephalin on the dopamine neurons of the rat substantia nigra and ventral tegmental area demonstrated by combined histofluorescence-immunocytochemistry. Brain Res. 194:1980;566-577.
33. Kemali D. Etude multicentrique de l'amineptine (Survector 100) en Italie. Clin. Neuropharmacol. 12:1991;S44-S53.
34. Kuschinsky K. Psychic dependence on opioids. Mediation by dopaminergic mechanisms in the striatum? Trends Pharmacol. Sci. 4:1981;287-289.
35. Leyssen J.E., Janssen P.M., Gommeren W., Wynants J., Pauwels P.J., Janssen P.A. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol. 41:1992;494-508.
36. Magnus-Ellenbroek B., Havemann-Reinecke U. Morphine-induced hyperactivity in rat. A rebound effect. Naunyn Schmiedbergs Arch. Pharmacol. 347:1993;635-642.
37. Maier E., Seligman M.E.P. Learned helplessness. Theory and evidence J. Exp. Psychol. Gen. 1:1976;3-46.
38. Maier E. Learned helplessness and animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 8:1984;435-446.
39. Maj J., Wedzony K. Repeated treatment with imipramine or amitriptyline increases the locomotor response of rats to (+)-amphetamine given into the nucleus accumbens. J. Pharm. Pharmacol. 37:1985;362-364.
40. 2 receptors in the rat brain. Eur. J. Pharmacol. 304:1996;49-54.
41. Maj J., Dziedzicka-Wasylewska M., Rogoz R., Rogoz Z. Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain. Eur. J. Pharmacol. 351:1998;31-37.
42. Martin P., Soubrié P., Simon P. Noradrenergic and opioid mediation of tricyclic-induced reversal of escape deficits caused by inescapable shock pretreatment in rats. Psychopharmacology (Berlin). 90:1986;90-94.
43. Martin P., Soubrié P., Simon P. The effect of monoamine oxydase inhibitors compared with classical tricyclic antidepressants on the learned helplessness paradigm. Prog. Neuropsychopharmacol. Biol. Psychiatry. 11:1987;1-7.
44. Martin P., Thiebot M.H., Puech A.J. Modèles animaux sensibles aux antidépresseurs. Implication des systèmes sérotoninergiques et noradrénergiques centraux Psychiatr. Psychobiol. 5:1990;209-217.
45. Martin P., Guillou N., Lacroix P., Billardon M. Effects of the coadministration of anxiolitic and antidepressant drugs in the learned helplessness paradigm. Impact of hydroxizine Encephale. 22:1996;270-279.
46. Muscat R., Papp M., Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol. Psychiatry. 31:1992;937-946.
47. Nomikos G.G., Damsma G., Wenkstern D., Fibiger H.C. Chronic desipramine enhances amphetamine-induced increase in interstitial concentrations of dopamine in the nucleus accumbens. Eur. J. Pharmacol. 195:1991;63-71.
48. 3H]NE-100 in guinea-pig brain. Life Sci. 57:1995;333-337.
49. Overmier J.B., Seligman M.E.P. Effects of inescapable shock upon subsequent escape and avoidance learning. J. Comp. Physiol. Psychol. 63:1967;23-39.
50. Plaznik A., Kostowski W. The effects of antidepressants and electroconvulsive shocks on the functioning of the mesolimbic dopaminergic system. A behavioral study Eur. J. Pharmacol. 135:1987;389-396.
51. Potter W.Z. Adrenoreceptors and serotonin receptor function. Relevance to antidepressant mechanism of action J. Clin. Psychiatry. 57(Suppl. 4):1996;4-8.
52. Pulvirenti L., Samanin R. Antagonism by dopamine, but not noradrenaline receptor blockers of the anti-immobility activity of desipramine after different treatment schedules in the rat. Pharmacol. Res. Commun. 18:1986;73-80.
53. Richelson E. Synaptic effects of antidepressants. J. Clin. Psychopharmacol. 16:1996;1S-8S.
54. Richelson E., Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes. Most antidepressants selectively block norepinephrine uptake Eur. J. Pharmacol. 16(Suppl. 2):1996;1S-7S.
55. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs. in vitro and in vivo receptor binding Psychopharmacology (Berlin). 124:1996;57-73.
56. Sherman D., Petty F. Neurochemical basis of the action of antidepressants on learned helplessness. Behav. Neurol. Biol. 30:1980;119-134.
57. Sherman D., Sacquitne J.L., Petty F. Specificity of the learned helplessness model of depression. Pharmacol. Biochem. Behav. 16:1982;449-454.
58. Somoza E., Galindo A., Bazan E., Guillamon A., Valenga A., Fuentes J.A. Antidepressants inhibit enkephalin binding to synaptosome-enriched fraction of rat brain. Neuropsychobiology. 7:1981;297-301.
59. Spyraki D., Fibiger H.C. Sensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur. J. Pharmacol. 74:1981;195-203.
60. Stengaard-Pedersen K., Schou M. Opioid receptors in the brain of the rat following chronic treatment with desipramine and electroconvulsive shock. Neuropharmacology. 25:1986;1365-1371.
61. Stewart J., Rajabi H. Initial increases in extracellular dopamine in the ventral tegmental area provide a mechanism for the development of desipramine-induced sensitization within the midbrain dopamine system. Synapse. 23:1996;258-264.
62. Su T.P., Schell S.E., Ford-Rice F.Y., London E.D. Correlation of inhibitory potencies of putative antagonists for sigma receptors in brain. Eur. J. Pharmacol. 148:1988;467-470.
63. Suhara T., Inoue O., Kobayasi K. Effect of desipramine on dopamine receptor binding in vivo. Life Sci. 47:1990;2119-2126.
64. 3 receptors mediated fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology (Berlin). 119:1995;15-19.
65. Tanda G., Frau R., Di Chiara G. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology (Berlin). 127:1996;83-87.
66. Tejedor-Real P., Mico J.A., Maldonado R., Roques B.P., Gibert-Rahola J. Effect of mixed (RB38A) and selective (RB38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol. Psychiatry. 34:1993;100-107.
67. Tejedor-Real P., Mico J.A., Maldonado R., Roques B.P., Gibert-Rahola J. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol. Biochem. Behav. 52:1995;145-152.
68. Thiebot M.H., Martin P., Puech A.J. Animal behavioural studies in the evaluation of antidepressant drugs. Br. J. Psychiatry. 160:1992;44-50.
69. Willner P. Validation criteria for animal models of human mental disorders. Learned helplessness as a paradigm case Prog. Neuropsychopharmacol. Biol. Psychiatry. 10:1986;677-690.
70. Willner P. Sensitization of dopamine D2 or D3-type receptors as a final common pathway in antidepressant drug action. Clin. Neuropharmacol. 18(Suppl. 1):1995;S49-S56.
71. Yoshioka M., Matsumoto M., Togashi H., Smuth C.B., Saito H. Opioid receptor regulation of 5-HT release from the rat hippocampus measured by in vivo microdialysis. Brain Res. 613:1993;74-79.